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ABSTRACT
Objective: The objective is to estimate willingness-to-pay (WTP) for phar-
macogenetic testing in the treatment of depression.
Methods: In a web-based discrete choice questionnaire, four attributes
were included: 1) number of changes in antidepressants before symptom
relief; 2) time with dosage adjustments due to adverse side effects and/or
lack of effects; 3) cost of pharmacogenetic testing; 4) probability of ben-
eﬁts from pharmacogenetic testing. Respondents were asked to choose
between two scenarios; 1) pharmacogenetic testing; and 2) an opt-out
option reﬂecting a scenario without pharmacogenetic testing. The indirect
utility model was assumed to be multiplicative in probability of beneﬁts
and reduced time with dosage adjustments as well as reduced number of
antidepressant changes.
Results: Most coefﬁcients had the expected signs and were statistically
signiﬁcant. WTP for avoidance of one change in antidepressant medication
is 1571 Danish Krone (DKK), whereas WTP for reducing the period with
dosage-adjustments by 1 month is DKK604. Both were statistically sig-
niﬁcantly different from zero.
Conclusion: If diagnosed with depression, peoples’ WTP for pharmaco-
genetic testing appears to exceed its price as long as there is a reasonable
probability for improvements in treatment (in the present case 10%).
Utility is associated with outcomes only. Hence, other modes of provision
of similar improvements in treatment may be valued equally highly. WTP
estimates and the associated policy implications appear to be robust
because they were unaffected by estimation model.
Keywords: depression, discrete choice experiment, pharmacogenetics,
preferences.
Introduction
Depression was rated as the leading cause of worldwide nonfatal
disability by the World Health Organization in 2003 [1]. In
Denmark, the prevalence of people needing treatment for depres-
sion is estimated to be 3.5%, although the risk of developing the
disease in a lifetime perspective is 15% [2].
Depression is difﬁcult to treat, and only 50% to 70% of
patients respond to initial pharmacotherapy [2–4]. Recom-
mended antidepressant dosages is based on comprehensive
plasma concentration levels, which is sought by taking account
of factors such as age, sex, other concomitant pharmaceuticals,
as well as alcohol consumption, coffee, cigarette, or drug abuse,
etc. For a large part of drugs, these recommended plasma-
concentration levels encompass rather wide intervals and
concentration–response curves are not well-established [5,6].
Also, the consequences of choosing one drug as ﬁrst treatment as
opposed to another is hard to assess [7–9]. Different antidepres-
sants are therefore tested successively to ﬁnd a potent drug with
a minimum of associated adverse drug reactions (ADRs)—a
well-known phenomena resulting in severe problems with non-
adherence to pharmacotherapy for as many as 30% to 60%
of patients [2,10]. Examples of common ADRs are dry mouth,
constipation, blurred vision, nausea, tremor, insomnia, and
cardiac disturbance [5].
The lack of robust evidence with regards to the optimal
choice of drug, as well as starting and maintenance dosages
has led to clinicians using an iterative approach to prescribing,
whereby therapy is started at low dosages which are then gradu-
ally increased to decrease the risk of severe life-threatening toxic
effects [4,11]. Consequently, this often leads to waiting time for
alleviation of symptoms in addition to the initial minimum of 2
to 3 weeks with pharmacotherapy before symptom relief. Fre-
quently subsequent dose-increases ends with a change in anti-
depressant medication and a new waiting process because
treatment was either ineffective or associated with intolerable
ADRs [4,7,12,13]. During this phase of treatment, patients may
continue to suffer and experience severe and uncontrolled symp-
toms and/or ADRs [2].
The costs of depression are immense [14–17] and in the
Swedish population, which has some resemblance with the
Danish, annual total costs were found to equal €11,000, of which
direct costs constituted €3800 [17]. Substantial costs are associ-
ated with treatment failure [18–20] as well as personal cost for
patients in terms of suffering and lost quality of life.
Taking Genetics into Account
Some studies have identiﬁed that genetic variation in the drug
metabolizing enzyme, CYP2D6, may be associated with indi-
viduals’ response to certain antidepressants (as well as some
antipsychotics), in terms of both risk of treatment failure as well
as prevalence of adverse drug reactions and observed plasma
concentration levels [21–23]. Knowledge about patients’ genetic
status with respect to this enzyme might reduce the length as well
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as number of periods with dosage adjustments as patients’ meta-
bolic capacity can be taken into consideration along with age,
sex, lifestyle, and concomitant pharmaceuticals from the very
beginning when the ﬁrst dosage of an antidepressant agent is
prescribed. This kind of personalized medicine—testing for
genetic differences between individuals when prescribing
medicines—is termed pharmacogenetic testing.
The beneﬁts of pharmacogenetic testing for the CYP2D6 gene
when prescribing antidepressants is compromised by the fact that
far from all antidepressants are metabolized this way [21,24].
Table 1 provides a list of substrates primarily metabolized by the
CYP2D6 [25]. Aside from that, the partly unknown and complex
nature of psychiatric diseases complicates the prediction of
response to pharmaceuticals, as this is also affected by individual
differences in pathways, receptors, disease pathology, as well as
lifestyle, age, sex, and concomitant pharmaceuticals [21,26–29].
Hence, in spite of a relatively high prevalence among Caucasians
where 20% to 30% have either no functioning CYP2D6
enzymes, reduced number of enzymes, or varying levels of dupli-
cations of the enzyme relative to the dominant part of Caucasians
[21,30–35], no evidence on the beneﬁts of pharmacogenetic
testing is available [4,36,37]. Chou et al. [38] found trends
toward greater number of ADRs and prolonged hospital stays
as well as increased costs among psychiatric patients with
genetically increased or decreased enzymatic activity. A large
population-based cohort study [4], which examined the inﬂuence
of genetically decreased enzymatic activity on intolerability of
antidepressants by studying dosages, frequency of switching to
another antidepressant, or discontinuation of pharmacotherapy,
found an increased risk of switching between antidepressants
among patients with decreased metabolic capacity as well as
lower mean antidepressant maintenance dosages in these patients
[4].
Studies indicate that pharmacogenetic testing for metaboliz-
ing enzymes in general might beneﬁt between 15% and 40% of
drug treatments, but numbers vary between studies [30,31,39]. A
conservative assumption based on expert opinion is that only 2%
to 5% of depressed patients tested would beneﬁt from pharma-
cogenetic testing of the CYP2D6 [40]. Ultimately, the beneﬁts of
testing will depend on the most frequently used antidepressant
(and the way this is metabolized) as well as the population under
investigation as the frequency of the “non-normal” deviant
metabolizers differs across ethnic groups [31]. Possible beneﬁts of
pharmacogenetic testing are reductions in the time-to-target-dose
as well as reductions in the number of changes in antidepressant
medication as patients can be characterized by whether they are
expected to be able to tolerate ordinary dosages or whether
dosages should either be decreased or increased, or if a pharma-
ceutical not primarily dependent on the CYP2D6 enzyme should
be chosen as ﬁrst choice.
Pharmacogenetic testing for changes in the CYP2D6 gene has
been introduced at one psychiatric hospital in Denmark and is
available at the price of DKK1630 (€219) [41]. A single blood
sample (or mouth swab) is required; and because our genes do
not change, the test will never need to be conducted again.
Other psychiatric hospitals are likely also to consider imple-
menting the pharmacogenetic test in the future. We therefore
wanted to see if pharmacogenetic testing for CYP2D6 and the
potential consequences for the treatment of depression would be
of any value to potential patients and if this could be modeled by
means of a discrete choice experiment. The purpose of this study
was to elicit the Danish populations’ preferences for the intro-
duction of routine pharmacogenetic testing among newly
diagnosed depressed patients about to be treated with antidepres-
sants. The aim was to estimate the monetary use value of the
pharmacogenetic test.
Methods
Discrete Choice Experiment
A discrete choice experiment (DCE) was used to elicit preferences
for pharmacogenetic testing among a panel of Danes, 18 to 65
years old. In a DCE, respondents are faced with hypothetical
choices between treatment scenarios that differ in terms of speci-
ﬁed attributes and attribute levels. The value of the good (in this
case the pharmacogenetic test) is determined by the magnitude of
these attributes, and by varying the levels of these in hypothetical
scenarios, respondents are forced to make trade-offs. Those
incremental changes in attributes which are relevant for respon-
dents’ choices can then be identiﬁed. On the basis of the relative
weighting of the attributes, a compensation variation measure
that conforms with demand theory is derived [42,43].
Survey Design
Seven hundred one respondents were e-mailed a link to the study
questionnaire sent out by an independent research agency
(Gallup) in August 2007. The sample was stratiﬁed by age, sex,
geographic location, and education. Participants in the research
panel from which respondents were sampled were recruited ran-
domly from telephone interviews and invited to participate in the
Internet-based research panel. Participation in the research panel
is rewarded by participation in a lottery.
The questionnaire was developed on the basis of a literature
review, expert opinion and three focus group interviews with
depressive patients. The focus group interviews were conducted
in an iterative manner from which problems related to the phar-
maceutical treatment of depression were speciﬁed in more detail
and related to those elements of the pharmaceutical treatment
that the pharmacogenetic test could have an impact upon. A
more detailed description of the development of the question-
naire and results from the focus group interviews are available in
English elsewhere [44]. From the focus group interviews, it was
clear that patients clearly prefer if the correct antidepressant
could be administered at the right dosage from the very begin-
ning of their pharmaceutical treatment. Two attributes found to
be of importance to patients’ experience of the pharmaceutical
treatment which could be affected by pharmacogenetic testing
were identiﬁed: 1) the number of changes in antidepressant medi-
cation before symptom relief; and 2) the time with dosage-
adjustments due to lack of effect and/or unacceptable ADRs.
These two attributes are hereafter called the effect-attributes and
both relates to the experience of the health improvement associ-
ated with the treatment. The number of changes in antidepres-
sant medication was important to patients because each change
represents a realization that the current antidepressant will not
be effective or is associated with intolerable ADRs, that time has
been wasted, and that a new course of treatment with associated
risks of ADRs must be initiated. Although changing antidepres-
sants was associated with a negative utility due to frustration and
the facing of new risks, the time with dosage adjustments was
found to be frustrating because of the waiting time and the lack
Table 1 Examples of antidepressants primarily metabolized by CYP2D6
Fluoxetine, Fluvoxamine, Paroxetine, Citalopram, Doxepin,Amitriptyline,
Imipramine,Trimipramin, Nortryptyline, Maprotilin, Clomipramine,
Venlafaxin, Mirtazapine, Mianserin [25].
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of symptom relief and/or intolerable ADRs, as well as the uncer-
tainty regarding the response of an increased or decreased
dosage.
In the questionnaire, it was clearly explained to respondents
that the number of changes and the total time with dosage
adjustments (across all medication attempts) could vary indepen-
dently. This is reality in practice, where a prescribing doctor may
choose to switch medications early in the process; or alternatively
opt for longer periods with dosage adjustment in an attempt to
avoid switching. Hence, a reduced number of changes may
involve longer or shorter total time with dosage adjustments, and
a longer dosage-adjustment period may involve fewer or more
medicine changes. Clinically, the relevance of the two attributes is
supported by evidence on increased number of antidepressant
changes as well as difference in maintenance dosages among
patients with genetically altered enzymatic capacity relative to
patients with normal capacity [4].
The pharmacogenetic tests’ ability to affect the two effect-
attributes depends upon whether the “ﬁrst choice” prescribed
antidepressant is metabolized by the CYP2D6 and whether the
patient has a non-normal metabolic capacity. Other factors such
as speciﬁc pathways, lifestyle, concomitant pharmaceuticals, etc.,
may also affect the effects of the pharmacogenetic test. Hence, a
signiﬁcant proportion of patients will not gain from pharmaco-
genetic testing, but at the time the test is performed, one cannot
determine who these individuals are. Consequently, we included
a third attribute representing the probability of getting any
beneﬁt (i.e., any reduction in the time with dosage adjustment
and any reductions in the number of antidepressant changes)
from the test. Finally, a price of the test was included, allowing
for the calculation of marginal willingness-to-pay (WTP)
estimates.
Each respondent was presented with eight choice-sets, each
containing two scenarios; one scenario represented treatment
outcomes with the pharmacogenetic test and the other repre-
sented a status quo scenario with treatment outcomes as stan-
dard practice is today without the pharmacogenetic test. This
status quo scenario represents an opt-out option [45]. In this
case, the opt-out option is speciﬁed in accordance with the
expected outcomes of current practice, and the respondent is
thereby provided with the necessary information required to
make an informed choice. Respondents were given a thorough
description of depression and the symptoms characterizing the
disease as well as the pharmacological treatment and the related
problems. The attributes were carefully explained and respon-
dents were told to think of the test as an insurance-policy “you
do not know whether you will beneﬁt, but you will have to pay
with certainty. If you do not beneﬁt your treatment outcome will
be equivalent to the scenario without the test.” Respondents
were faced with the following question: “Imagine that you have
just been diagnosed with depression for the ﬁrst time. Which of
the two treatment possibilities would you choose?” An example
of a choice set is shown in Table 2.
The treatment scenario without the pharmacogenetic test was
constructed as a ﬁxed status quo scenario and represented a
treatment proﬁle for a group of moderately to severely depressed
patients’ ﬁrst episode of depression. Levels for the two effect-
attributes characterizing this scenario were based on median ﬁrst
episode values obtained in a previous study among moderately to
severely depressed patients treated without the test in accordance
with current practice [46]. The levels were four changes in anti-
depressants and 5 months with dosage adjustments. A positive
price-attribute was associated with the pharmacogenetic test sce-
nario. Respondents were informed that on an average, having the
test would not affect out-of-pocket pharmaceutical expenses.
In the pharmacogenetic treatment scenario, attribute levels
were conservatively reduced by one or two changes in antide-
pressants, and the period with dosage adjustments was reduced
by 2 or 4 months. These values were entered into the regression
analyses by way of difference coding as reductions of one and
two, and two and four, respectively. To secure that our price-
attribute covered both a lower as well as an upper bound of WTP
[47], eight levels were chosen for the price attribute in the phar-
macogenetic treatment scenario, ranging from DKK200 (€27) to
DKK18,000 (€2420). The price of the test was stated as an
out-of-pocket, once in a lifetime payment.
The prevalence of genetically non-normal metabolizers in
Denmark is almost 20% [35]. In the present study, we assumed
that half of these could beneﬁt from pharmacogenetic testing.
Hence, the base-case probability of beneﬁting from the test was
set at 10%. In other stated preference studies, it has been found
that respondents are frequently insensitive to scope, and this
problem is enhanced when respondents face probabilities
[48,49]. We therefore chose to present respondents with another
probability level to test if individuals are indeed sensitive to the
level of probability. This level was set at 50% to distinguish it
from the base-level. The probability attribute was thus coded as
a dummy variable (which equaled 1 if the probability was 50%;
otherwise zero) and the associated coefﬁcient was used to test for
sensitivity to scope. Attributes and attribute levels as well as
coding are shown in Table 3.
Statistical Design
A fractional factorial experimental design optimizing D-
efﬁciency was generated in SAS [50] using the MktEx macro,
resulting in a design with 32 hypothetical alternatives. These 32
Table 2 Example of a choice set presented for the respondents in the
discrete choice experiment
Imagine you have just been diagnosed with
depression for the ﬁrst time.Which of the
two treatment possibilities would you
choose?
Genetic
test
No genetic
test
Likelihood of getting improvements from the
test:
50%
Price of the test (expenses for medicine
remains constant):
DKK18.000 DKK0
Number of changes in antidepressant
medicine:
2 changes 4 changes
Time with dosage adjustments due to lack of
effect and/or unacceptable adverse side
effects:
3 months 5 months
DKK, Danish Krone.
Table 3 Attributes and attribute levels used in the discrete choice
experiment
Attribute
Attribute levels (coding)
in the scenario representing
pharmacogenetic testing
Likelihood of getting improvements
from the test:
10% (0), 50% (1)
Price of the test DKK200; DKK600; DKK1000;
DKK1500; DKK3000;
DKK6000; DKK9000;
DKK18,000
Number of changes in antidepressant
medicine:
2 changes (2), 3 changes (1)
Time with dosage adjustments due to
lack of effect and/or unacceptable
adverse side effects:
1 months (4), 3 months (2)
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alternatives were distributed across four blocks of eight using the
MktBlock macro in SAS that creates a blocking factor, which is
uncorrelated with every attribute of every alternative while
ensuring the maximum degree of design efﬁciency. The 32 alter-
natives were each paired with the ﬁxed status quo alternative
such that a total of 32 choice sets were constructed. The design
is available from the authors on request.
In the design, we allowed for two-way interaction effects to
be estimated between the probability of getting an effect and the
attributes on the effect i.e., reductions in the number of antide-
pressant changes and time with dosage adjustments.
Theory of Expected Utility
Using the two attributes on “number of changes in medicine” and
“timewith dosage adjustments before symptom relief” to describe
the pharmacogenetic test (the effect-attributes), we implicitly
assume that reductions in these represent the total observable
value of the pharmacogenetic test, i.e., its utility-generating prop-
erties. As the underlying assumption of theDCE is that individuals
are utility-maximizing, we expect respondents to maximize utility
with respect to the two effect-attributes subject to the price of the
pharmacogenetic test. The utility gain depends upon the probabil-
ity by which the effects will be provided. According to the theory
of expected utility (EUT), we assume that the expected utility is a
multiplicative function of probability and effect. Respondents are
thus expected to trade among treatment scenarios in a way that
maximizes their utility from the effects of the test subject to the
probability of getting these and the price. Hence, we assume
that the utility function can be represented by the following
speciﬁcation:
Δ Δ Δ
Δ
U ASC x x
x
test test price change
time change
= + + +
+
ˆ ˆ ˆ
ˆ ˆ
α β β
β β
1 2
3 ∗
∗
+prob
time prob
Δ Δ
Δ Δ
x d
x d
2 50
3 50βˆ (1)
The coefﬁcient βˆprice represents the marginal disutility of the price
of the test (because this has to be paid in addition to existing
costs of treatment without pharmacogenetic testing), and
βˆchange and βˆtime represents the utility of marginal changes in any
of the two effect-attributes when the probability of effect is 10%
(reference level). Dx2Dd50 and Dx3Dd50 constitute added utility
associated with changes in the effect-attributes when the prob-
ability level is 50% (d50 equals one if the probability is 50%; else,
zero). The coefﬁcient αˆ test for the alternative speciﬁc constant
(ASC) captures any utility associated with the test per se.
Econometric Analysis
The data were analyzed using the conditional logistic regression
procedure, clogit, in the statistical software package of STATA
version 9.2 (Stata Corp., College Station, TX). WTP-estimates
were calculated as marginal rates of substitution (MRS) between
the coefﬁcients of the effect-attributes and the coefﬁcient on
price, e.g., MRS change price= −Δ Δˆ ˆβ β . Conﬁdence intervals (CI) for
WTP-estimates were calculated using the parametric bootstrap-
ping procedure speciﬁed by Krinsky-Robb with 10,000 replica-
tions [51–53].
To test for preference heterogeneity across relevant groups
without introducing problems of scale [54], we compared WTP-
estimates in a number of stratiﬁed analyses or included inter-
action terms between the attributes and dummy variables
representing sub-groups. We tested 1) if WTP differed across
income groups with a household income above or below
DKK350,000 (€47,000); 2) if current or former pharmaceutical
treatment for depression among respondents affected WTP; 3) if
prior diagnosis of depression and/or having friends or relatives
with present or past diagnosis of depression and experience with
antidepressants affected WTP; 4) if there was a difference in WTP
across sex, age, and education; and 5) if perceived difﬁculty in
answering the DCE-questions was associated with differences in
WTP-estimates.
Results
A total of 701 questionnaires were sent out. Four respondents
were noneligible to participate, 74 did not wish to participate, 39
did not complete any of the DCE questions, and 261 did not
reply at all. A total of 323 completed questionnaires were
returned, providing a response rate of 46%.
Respondent Descriptives
Males represented 47% of respondents. Compared with the
general Danish population, respondents aged 18 to 24 years were
slightly under-represented and respondents with a high level of
education were over-represented [55]. Nineteen respondents did
not like the idea of pharmacogenetic testing or/and would never
want to have the test. Some of these were among the 43 non-
traders always choosing the no-test scenario. As we wanted to
estimate the use value of the test, these respondents were
excluded because we interpret these as being nonusers within the
given spectrum of attribute levels. Three respondents had already
had the pharmacogenetic test and were also excluded. This left us
with a total sample of 277 individuals each answering eight
choice sets.
Preferences for the Pharmacogenetic Test
Results of the conditional logistic regression analysis are pre-
sented in Table 4. As expected, the coefﬁcient on the price
attribute is negative, indicative of decreasing utility as the price of
Table 4 Results from the DCE assuming a multiplicative utility function in accordance with expected utility theory
Coefﬁcient t-value Prob > |t| WTP (DKK) 90% CI (DKK)
ASC 0.3999 0.47 0.637 430 -1007 1860
Price -0.0003 -19.29 0.000 — — —
Changes (reductions in medicine changes) 0.3999 3.42 0.001 1571 809 2331
Changes*d50 (added utility if probability of effect increases to 50%) -0.022 -0.15 0.884 -70 -1055 903
Time (reduction in the time with dosage adjustments) 0.1528 2.62 0.009 604 230 986
Time*d50 (added utility if probability of effect increases to 50%) 0.1655 2.22 0.027 645 162 1135
N (observations/respondents) 4432/277
AIC* 2354
LR chi-square 730.12
Pseudo R2 0.2377
*AIC = 2 k - 2 ln (L), where k is the number of parameters in the model and L is the maximized value of the likelihood function for the estimated model.
AIC,Akaike information criterion; CI, conﬁdence interval; DKK, Danish Krone;WTP, willingness-to-pay.
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the test increases. The coefﬁcients of the effect-attributes are
positive, signifying a utility increase associated with decreases in
the number of antidepressant changes or reductions in time with
dosage adjustments. This is all in accordance with a priori expec-
tations and the coefﬁcients are statistically signiﬁcant (P > |t| less
than 0.01). The coefﬁcient of the interaction term between
changes in antidepressant medicine and probability is unexpect-
edly negative, but not statistically signiﬁcantly different from
zero, although the interaction between the time-attribute and
probability is positive and signiﬁcantly different from zero
(P = 0.027), though smaller than expected (according to EUT).
Preferences for reductions in the number of changes in antide-
pressant products do not seem to be affected by the probability
level at which improvements are given. The constant represents
the value of the pharmacogenetic test per se, i.e., irrespective of
its effects on treatment outcome. It is statistically insigniﬁcant,
which implies that the value of the test is associated with out-
comes only.
MarginalWTP
Estimates of WTP for a marginal change in attributes are also
shown in Table 4, including 90% CIs. The WTP estimate for a
10% probability of a reduction of one in the number of antide-
pressant changes is DKK1571 (90% CI DKK809–2331) and the
WTP for a reduction of 1 month in the time with dosage adjust-
ments with 10% probability is DKK604 (90% CI DKK230–
986). WTP for reductions in a number of changes is not
statistically higher when the probability of obtaining this gain is
50%, although WTP for an increase in the chance of obtaining a
month of reduction in the time with dosage adjustment to 50%
is DKK645 (90% CI DKK162–1135). The total value of 1 month
reduction in the time with dosage-adjustments with 50% prob-
ability is thus DKK1249. The CI for the WTP for the ASC is wide
and not statistically signiﬁcantly different from zero, signifying
that on average people only value the pharmacogenetic test by
the reductions in the attributes, although some might value the
more intangible beneﬁts of the test as well because it is slightly
positive.
Overall, the results imply that if the pharmacogenetic test
with a chance between 10% and 50% can reduce the number of
antidepressant changes by one and shorten the dosage adjust-
ment period by 1 month, the WTP for the pharmacogenetic test
exceeds the price of the test (current price is DKK1630).
Subgroup Analyses
Including an interaction term between a dummy (equal to one for
high-income households; else, zero) and the price attribute indi-
cated that WTP for the test differed between respondents with
different levels of income. This was expected and indicates that
respondents have taken budget constraints into consideration
when they completed the DCE. Almost 17% of the respondents
had been diagnosed with depression by their physician. Most of
these (81%; n = 35) had also been treated with antidepressants.
As the choice sets were designed with two hypothetical scenarios
and these respondents still constituted potential users of phar-
macogenetic testing, the respondents were not excluded. We
hypothesized that preferences for the pharmacogenetic test might
be affected by previous experience with antidepressants. Inclu-
sion of an interaction term between the attribute on number of
antidepressant changes and a dummy variable (equal to one if
respondents had been treated with antidepressants; else, zero)
demonstrated no statistically signiﬁcant differences between
those with and without experience. We also tested for differences
in preferences across groups with a presumed different level of
knowledge of depression. Sixty-ﬁve percent of the respondents
knew somebody among their nearest friends or family who had
been treated pharmacologically for depression, and some of these
were among the 17% who had been diagnosed with depression
themselves. Including an interaction term between the time-
attribute and a dummy variable (equal to one if knowledge of
depression; else zero), suggested no statistically signiﬁcant differ-
ences in preferences because of knowledge. We also tested for
sex-differences, age-related differences, and educational differ-
ences but found no impact on preferences. Finally, we tested
if reported self-perceived difﬁculty in answering the choice-
questions could be taken as a marker of preference heterogeneity
among respondents. Difﬁculty in answering the choice questions
was associated with insigniﬁcant WTP-estimates for both effect-
attributes and a clear tendency to choose on the basis of price
alone. In sum, we found no evidence of heterogeneity in prefer-
ence structures because of personal experience of antidepressant
medication, knowledge of the disease, or sex, age, and education.
Discussion
Internal Validity
The results of the discrete choice exercise, conducted among a
random sample of the Danish population who is to imagine
having been recently diagnosed with depression, suggest that the
stated expected use value of pharmacogenetic testing exceeds the
current price of the test, even if the test offers relatively small
expected gains. If, for example, the pharmacogenetic test
provides a 1-month reduction in time with dosage-adjustments as
well as one change less in antidepressant products, with a prob-
ability between 10% to 15%, the mean WTP among potential
users exceeds the cost of the pharmacogenetic test (current price
is DKK1630). The price of the test does however not cover the
entire costs of the test because blood samples have to be taken
and the results interpreted. Such analyses are associated with
marginal resource consumption in terms of labor costs. Conse-
quently, pharmacogenetic testing will only be associated with a
welfare gain if the marginal labor costs associated with perform-
ing and analyzing the test are small, or if the beneﬁts of the
pharmacogenetic test exceed the 10% probability of reducing the
number of antidepressant changes by one and the dosage adjust-
ment period by 1 month.
The small or statistically insigniﬁcant coefﬁcients associated
with the interaction terms between the effect attributes and the
probability dummy variable (equal to one if 50%; else, zero)
suggests that individuals are either insensitive to the level of
probability, or that respondents’ preferences in some way do not
accord with EUT. There has been much criticism of EUT and its
underlying assumptions [56,57], and studies have shown that
when respondents face gambles, they tend to use decision heu-
ristics that are not in accordance with EUT [49,58–64]. Some of
these studies have shown that when facing gambles, respondents
tend to focus either on outcomes or probabilities rather than
expected value. Our study appears to suffer from similar prob-
lems. We therefore tested if a model in which outcome and
probability entered the utility function as additive components,
rather than in a multiplicative manner provided a better ﬁt to the
data. This was not the case (Akaike Information Criterion of
2377 compared with 2354). With the additive model speciﬁca-
tion, all coefﬁcients except the ASC were highly statistically
signiﬁcant (P > |t| less than 0.001). The WTP for an increase in
the probability of an effect from 10% to 50% was estimated to
be DKK1984 (SD 403). Our WTP-estimates were relatively unaf-
fected by choice of model and our results seem to be fairly robust.
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We conducted a number of stratiﬁed analyses to compare
WTP for the pharmacogenetic test across subgroups as well as
test for preference homogeneity. These showed a large degree of
homogeneity across strata except for that of income, which con-
ﬁrmed decreasing marginal utility of income and increasing
price-insensitivity with rising income, as would be expected theo-
retically. For a subgroup of respondents reporting difﬁculties
with the DCE questions, choices seemed to be based primarily on
the level of the price attribute. This consequently led to a higher
WTP for the test itself (the ASC) and lower WTP-estimates for
marginal changes in the effect-attributes.
External Validity
Respondents aged 18 to 24 were slightly underrepresented, and
people with higher education and females were over-represented
relative to the Danish population. This result may be due to the
fact that the questionnaire was distributed electronically via
email. Nevertheless, in Denmark, the majority of the population
has access to the Internet in their homes, and email is a common
source of communication [65]. Hence, we do not think that the
distribution method in itself has introduced a severe bias in
representation. The observed bias is more likely to be due to
interest, ability, and availability of time. Only if the younger
and/or highly educated people have markedly different prefer-
ence structures in relation to pharmacogenetic testing does the
small bias in representation introduce bias in the presented
results. Subgroup analyses showed that sex, youth, and a high
level of education had no impact on preference structures.
The levels of the attributes applied in the status quo scenario
were based on estimates obtained from a similar DCE conducted
among patients, where respondents were asked about their expe-
rienced number of changes in antidepressants and experienced
time with dosage adjustment for their ﬁrst episode of depression
[46]. A majority of the interviewed respondents were likely to be
moderately to severely formerly or currently depressed patients.
Assuming the marginal utility of reductions in the effect-
attributes is affected by the absolute levels of the effects-
attributes presented in the status quo scenario, the results
presented here are only representative of preferences for pharma-
cogenetic testing among moderately to severely depressed
patients.
Design of the Scenarios
The price of the test was presented as an out-of-pocket once-in-
a-lifetime payment. Treatment in the Danish health-care system is
primarily free of charge and collectively ﬁnanced by taxes, but
there are relatively high copayments on dentist services and phar-
maceuticals. Because the pharmacogenetic test is very closely
linked to pharmacotherapy, the choice of an out-of-pocket
payment vehicle is unlikely to severely impair the theoretical
realism of the presented scenarios. We observed 43 nontraders
always choosing the opt-out alternative, and it is likely that some
of these have been protest-voters, unwilling to choose the test
because of an aversion to out-of-pocket payment. An alternative
payment vehicle such as increases in income taxes could have
been applied to avoid protest bidding, but this would have led to
other problems. Payment via income tax would involve paying
annually over a lifetime, for what is actually a once-in-a-lifetime
investment. Hence, even minute levels of annual tax-payments
would have constituted large and most likely overestimated WTP
values for the pharmacogenetic test. Thus, we chose the more
conservative approach, acknowledging that the WTP values
based on out-of-pocket payment may provide WTP-estimates
that underestimate the value of the pharmacogenetic test because
of protest bidding.
The pharmacogenetic test has not yet been tested in larger
randomized controlled trials, and the efﬁcacy of the test is
unknown. The chosen level for the probability attribute was
consequently based on assumptions with regards to the percent-
age of patients taking antidepressants metabolized by CYP2D6
as well as the number of patients with genetic and nongenetic
characteristics affecting the beneﬁts of pharmacogenetic testing.
In clinical settings where the predominantly used antidepres-
sants are selective serotonin reuptake inhibitors (SSRI), the like-
lihood of beneﬁting from the test is likely to be lower than the
10% assumed in this study (because the SSRIs are metabolized
by CYP2D6 to a lesser extent). In contrast, settings where tri-
cyclic antidepressants products are predominantly used would
most likely attain a larger probability of beneﬁt than the 10%
(because of larger dependence on CYP2D6-metabolism among
these products). Also, in populations with a larger frequency of
“non-normal” metabolizers, e.g., in Africans, beneﬁts will be
larger, although the opposite is the case in populations with a
lower frequency, e.g., in Asian populations. Nevertheless, clini-
cal and genetic research within the area is expanding so fast that
even if the present “true” beneﬁt level were available it would
most likely be outdated within a few years. In addition, phar-
macogenetic testing for CYP2D6-polymorphisms is likely to be
beneﬁcial in relation to pharmaceutical treatments for several
conditions because other pharmaceuticals than antidepressants
are metabolized by the CYP2D6-enzyme. Finally the effects of
pharmacogenetic testing for other genetic changes than those of
the CYP2D6, i.e., in other metabolizing enzymes and/or clinical
relevant pathways, is likely to also inﬂuence the potential ben-
eﬁts of pharmacogenetic testing in depression.
Therapeutic drug monitoring (TDM) using probe drugs, or
phenotyping as it is also called, has the potential of delivering the
same treatment improvements as pharmacogenetic testing [7].
The results from phenotyping are more precise, but not stable as
weight, drinking, and smoking habits, etc., can alter an individu-
als’ metabolizing capacity, thus necessitating the conduction of
phenotyping tests at each new disease episode. TDM can also be
used with antidepressants, but then only after pharmacotherapy
has been initiated and then plasma levels are measured at
repeated intervals. A debate about whether pharmacogenetic
testing is superﬂuous if routine TDM is used exists among prac-
titioners. As our results indicate, respondent’s value the out-
comes associated with the pharmacogenetic test but not the test
per se. Thus, the demand for pharmacogenetic testing observed
in the present study may not reﬂect the demand in real life if
TDM (in either shape) is an option. Future studies investigating
preferences for TDM versus pharmacogenetic testing are there-
fore recommended.
Conclusion
Respondents have preferences for reductions in the number of
changes in antidepressant products as well as reductions in the
time with dosage adjustments due to adverse side effects and/or
lack of effect. Assuming that a pharmacogenetic test is able to
offer a 10% chance of one change less in antidepressant products
and a reduction of 1 month in the total time with dosage adjust-
ments, respondents are willing to pay an amount which is greater
than the actual price of the pharmacogenetic test and the intro-
duction of such a test will be improving welfare. The value of
reductions in the number of changes in antidepressants is higher
than reductions in the time with dosage adjustments, and 2
months of dosage adjustments are preferred if it can prevent one
change in antidepressant medication. This is valuable informa-
tion when doctors choose their prescription strategy.
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Subgroup analyses indicate that preferences for this kind
of pharmacogenetic testing for CYP2D6 are consistent across
groups with different levels of knowledge of depression, suggest-
ing that the hypothetical DCE exercise was well-understood by
the respondents. The fact that respondents are insensitive to the
scope of the probability attribute does raise concern. It is
however reassuring that the valuation of the pharmacogenetic
test is robust as WTP-estimates were relatively unaffected by
choice of model speciﬁcation.
Source of ﬁnancial support: Center for Pharmacogenomics at the Univer-
sity of Copenhagen as well as the Danish Institute for Health Services
Research
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